A 23% market share of new prescriptions for hepatitis C in the US has been captured by Roche's antiviral agent PEG-interferon (IFN)- -2a

Author：  

Publisher： Adis International

ISSN： 1173-5503

Source： PharmacoEconomics and Outcomes News, Vol.1, Iss.402, 2003-01, pp. : 12-12

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Schering-Plough's peginterferon (PEG IFN)- -2b plus ribavirin [Peg-Intron plus Rebetol] has been granted priority review status in Japan for a new indication

By  

Inpharma, Vol. 1, Iss. 1495, 2005-01 ,pp. : 23-23

Adis International

Access to resources Recommend Favorite

PEG-Interferon Alfa-2b for Acute Hepatitis C: A Review

By  

Mini Reviews in Medicinal Chemistry, Vol. 7, Iss. 8, 2007-08 ,pp. : 839-843

Bentham Science Publishers

Access to resources Recommend Favorite

PEG IFN- -2a improves QOL in hepatitis C

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 403, 2003-01 ,pp. : 10-10

Adis International

Access to resources Recommend Favorite

Recurrent hepatitis C virus (HCV) infection after liver transplantation "can be safely treated" with PEG interferon (IFN)- -2b and ribavirin

By  

Inpharma, Vol. 1, Iss. 1429, 2004-01 ,pp. : 16-16

Adis International

Access to resources Recommend Favorite

PEG IFN- -2a flies ahead in chronic hepatitis C

By  

Inpharma, Vol. 1, Iss. 1268, 2000-01 ,pp. : 8-8

Adis International

Access to resources Recommend Favorite